Logo

SLQT

SelectQuote, Inc.

SLQT

SelectQuote, Inc. • NYSE
$1.45 ▼ -2.03% (-0.03)
Market Cap $255.16 M
52w High $6.86
52w Low $1.33
Dividend Yield 0%
P/E 145
Volume 462.46K
Outstanding Shares 175.97M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $328.811M ▼ $107.677M ▼ $-30.459M ▼ -9.263% ▼ $-0.258 ▼ $-21.555M ▼
Q4-2025 $345.102M ▼ $116.47M ▼ $12.868M ▼ 3.729% ▼ $-0.021 ▼ $26.476M ▼
Q3-2025 $408.16M ▼ $144.385M ▼ $26.022M ▼ 6.375% ▼ $0.12 ▼ $59.933M ▼
Q2-2025 $481.069M ▲ $152.79M ▲ $53.236M ▲ 11.066% ▲ $0.31 ▲ $68.337M ▲
Q1-2025 $292.263M $108.983M $-44.546M -15.242% $-0.26 $-6.39M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $10.745M ▼ $1.207B ▼ $660.05M ▼ $546.926M ▼
Q4-2025 $32.4M ▼ $1.249B ▼ $673.838M ▼ $575.518M ▲
Q3-2025 $80.106M ▲ $1.296B ▲ $738.008M ▼ $557.825M ▲
Q2-2025 $12.104M ▲ $1.279B ▲ $953.165M ▲ $326.002M ▲
Q1-2025 $10.444M $1.147B $877.432M $269.439M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-30.459M ▼ $-21.623M ▲ $-3.984M ▼ $4.24M ▲ $-21.367M ▲ $-25.607M ▲
Q4-2025 $12.868M ▼ $-37.482M ▼ $-3.111M ▲ $-8.563M ▼ $-49.156M ▼ $-37.983M ▼
Q3-2025 $26.022M ▼ $71.12M ▲ $-3.357M ▼ $4.826M ▼ $72.589M ▲ $70.171M ▲
Q2-2025 $53.236M ▲ $-28.694M ▼ $-2.272M ▲ $34.155M ▲ $3.189M ▲ $-30.966M ▼
Q1-2025 $-44.546M $-16.61M $-2.574M $-13.062M $-32.246M $-19.184M

Revenue by Products

Product Q2-2025Q3-2025Q4-2025Q1-2026
Pharmacy
Pharmacy
 $180.00M ▲$190.00M ▲$210.00M ▲$220.00M ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Service
Service
 $300.00M ▲$220.00M ▼$130.00M ▼$110.00M ▼

Five-Year Company Overview

Income Statement

Income Statement SelectQuote’s sales have grown strongly again after a rough patch, and the business has moved from sizable losses back to modest profitability. Gross margins have improved as the company gets more efficient and leans into higher‑value healthcare services. That said, profits are still relatively thin and have been quite volatile over the last few years, which suggests the model is sensitive to marketing spend, commission rates from carriers, and operating discipline. Overall, the trend line is better, but the earnings base does not yet look fully stable or mature.

Balance Sheet

Balance Sheet The balance sheet shows a company that is healthier than a few years ago but still carries a meaningful debt load. Total assets have held fairly steady, while equity has been rebuilt after earlier losses, helped by recapitalization efforts. Debt has been trimmed but remains significant relative to the size of the business, and the cash balance is fairly light, leaving less cushion against shocks. The direction is positive—less leverage and more equity support—but financial flexibility is not yet abundant, so execution and funding choices remain important.

Cash Flow

Cash Flow Cash generation has been a weak spot. Historically, operating cash flow has swung around, with periods of outflows as the company invested heavily in growth and absorbed working capital needs. More recently, cash use has narrowed toward breakeven, helped by better profitability and tighter spending, but the record is not yet one of consistently strong, recurring free cash flow. Capital spending needs are low, which helps, but the combination of modest cash on hand and uneven cash inflows means liquidity and cash discipline are key areas to watch.

Competitive Edge

Competitive Edge SelectQuote occupies a differentiated niche as a tech‑enabled, agent‑assisted broker with a strong focus on the senior market and a growing healthcare services arm. Its multi‑carrier platform, brand recognition, and large licensed agent force give it reach and credibility versus smaller brokers and single‑carrier agents. The SelectRx pharmacy and related services deepen customer relationships and can create stickier, recurring revenue. However, the company faces intense competition from other brokers, insurtech platforms, and insurers selling directly to consumers. On top of that, the recent Department of Justice complaint introduces regulatory and reputational risk that could weigh on relationships with carriers and customers until resolved.

Innovation and R&D

Innovation and R&D Innovation at SelectQuote is centered on software, data, and service design rather than traditional lab‑style R&D. The company has built proprietary tools for its agents, uses data analytics and machine learning to target leads and route calls, and deploys conversational AI to handle parts of the enrollment and service process. These efforts are aimed at raising agent productivity, lowering customer acquisition costs, and improving the customer experience. In parallel, the build‑out of SelectRx and a broader healthcare services ecosystem is a strategic innovation that moves the company from one‑time policy sales toward ongoing service relationships. The key questions are whether these technology and healthcare investments keep differentiating the platform and whether they translate into durable cost advantages and higher, more predictable margins over time, particularly given regulatory scrutiny.

Summary

SelectQuote looks like a business in the middle of a major evolution—from a traditional, marketing‑heavy insurance broker to a more integrated, technology‑driven healthcare services platform. Financially, revenue and margins have recovered from earlier setbacks, and the company has returned to profitability with some balance sheet repair. At the same time, debt is still meaningful, cash is limited, and cash flow has not yet become consistently strong, so the financial foundation, while improving, remains somewhat fragile. Strategically, the company’s hybrid of technology and human agents, its focus on the senior market, and the expansion of SelectRx and related services create a potentially attractive position with deeper, recurring customer relationships. Yet the environment is competitive, customer acquisition is expensive, and regulatory and legal risks—highlighted by the recent DOJ case—are non‑trivial. The company’s future will largely depend on its ability to keep improving profitability and cash generation, scale its healthcare ecosystem, prove out the returns on its AI and automation initiatives, and navigate regulatory and legal challenges without undermining the trust that underpins its business model.

NEWS

November 24, 2025 · 4:28 PM UTC

Berman Tabacco Announce s Investigation of SelectQuote, Inc. (NYSE:SLQT)

Read more

November 10, 2025 · 11:07 AM UTC

Berman Tabacco Announces Investigation of SelectQuote, Inc. (NYSE:SLQT)

Read more

November 6, 2025 · 7:30 AM UTC

SelectQuote, Inc. Reports First Quarter of Fiscal Year 2026 Results

Read more

October 23, 2025 · 7:30 AM UTC

SelectQuote to Release Fiscal First Quarter 2026 Earnings on November 6

Read more

October 15, 2025 · 4:15 PM UTC

SelectQuote's Healthcare Select Research Uncovers Critical Gaps in Care, Highlighting Urgent Need for Personalized Healthcare Solutions

Read more